Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.41 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.40 |
| ▸ | PANK3 | Q9H999 | 3/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15578958 | 0.80 | EGLN1 (0.70) | EGLN1ALKBH1 | |
| SCHEMBL15167447 | 0.78 | EGLN1 (0.52) | EGLN1ALKBH1LMNA | |
| SCHEMBL23013399 | 0.77 | CA1 (0.42) | — | |
| SCHEMBL14167780 | 0.77 | CHRM4 (0.51) | KDM4EALDH1A1L3MBTL1CHRM4 | |
| SCHEMBL15167521 | 0.77 | KCNJ1 (0.49) | EGLN1LMNASTING1 | |
| SCHEMBL25353915 | 0.75 | EGLN1 (0.45) | EGLN1EGLN2LMNA | |
| SCHEMBL15167695 | 0.74 | EGLN1 (0.43) | EGLN1LMNA | |
| SCHEMBL15167816 | 0.74 | NPC1 (0.50) | EGLN1ALDH1A1L3MBTL1LMNA | |
| SCHEMBL25778557 | 0.71 | ALDH1A1 (0.44) | EGLN1KDM4EALDH1A1L3MBTL1PANK3 | |
| SCHEMBL28835764 | 0.71 | KDM4E (0.44) | EGLN1KDM4EALDH1A1L3MBTL1EGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2837627-B1 | AMIDOPYRIDINE DERIVATIVE, AND USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2017-01-18 | — | — | EP | disclosed |
| US-9527859-B2 | Amidopyridine derivative and use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-12-27 | — | — | US | disclosed |
| US-20150065715-A1 | AMIDOPYRIDINE DERIVATIVE AND USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-03-05 | — | — | US | disclosed |
| EP-2837627-A1 | AMIDOPYRIDINE DERIVATIVE, AND USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2015-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065715-A1 | AMIDOPYRIDINE DERIVATIVE AND USE THEREOF | IL5, IL2, IL4 | EGLN1 2985/4885KDM4E 3425/4885ALDH1A1 1089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.